229 related articles for article (PubMed ID: 18067883)
21. Developing and shedding inhibitions: how MHC class II molecules reach maturity.
Busch R; Mellins ED
Curr Opin Immunol; 1996 Feb; 8(1):51-8. PubMed ID: 8729446
[TBL] [Abstract][Full Text] [Related]
22. Human invariant chain isoform p35 restores thymic selection and antigen presentation in CD74-deficient mice.
Genève L; Chemali M; Desjardins M; Labrecque N; Thibodeau J
Immunol Cell Biol; 2012 Oct; 90(9):896-902. PubMed ID: 22689013
[TBL] [Abstract][Full Text] [Related]
23. DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide.
Sherman MA; Weber DA; Jensen PE
Immunity; 1995 Aug; 3(2):197-205. PubMed ID: 7648393
[TBL] [Abstract][Full Text] [Related]
24. Truncation of the class II beta-chain cytoplasmic domain influences the level of class II/invariant chain-derived peptide complexes.
Smiley ST; Rudensky AY; Glimcher LH; Grusby MJ
Proc Natl Acad Sci U S A; 1996 Jan; 93(1):241-4. PubMed ID: 8552613
[TBL] [Abstract][Full Text] [Related]
25. Achieving stability through editing and chaperoning: regulation of MHC class II peptide binding and expression.
Busch R; Rinderknecht CH; Roh S; Lee AW; Harding JJ; Burster T; Hornell TM; Mellins ED
Immunol Rev; 2005 Oct; 207():242-60. PubMed ID: 16181341
[TBL] [Abstract][Full Text] [Related]
26. MHC class II loading of high or low affinity peptides directed by Ii/peptide fusion constructs: implications for T cell activation.
Gregers TF; Fleckenstein B; Vartdal F; Roepstorff P; Bakke O; Sandlie I
Int Immunol; 2003 Nov; 15(11):1291-9. PubMed ID: 14565927
[TBL] [Abstract][Full Text] [Related]
27. Conformational heterogeneity of MHC class II induced upon binding to different peptides is a key regulator in antigen presentation and epitope selection.
Sadegh-Nasseri S; Natarajan S; Chou CL; Hartman IZ; Narayan K; Kim A
Immunol Res; 2010 Jul; 47(1-3):56-64. PubMed ID: 20066513
[TBL] [Abstract][Full Text] [Related]
28. A central role for HSC70 in regulating antigen trafficking and MHC class II presentation.
Deffit SN; Blum JS
Mol Immunol; 2015 Dec; 68(2 Pt A):85-8. PubMed ID: 25953005
[TBL] [Abstract][Full Text] [Related]
29. Non-covalent presentation of sulfamethoxazole to human CD4+ T cells is independent of distinct human leucocyte antigen-bound peptides.
Burkhart C; Britschgi M; Strasser I; Depta JP; von Greyerz S; Barnaba V; Pichler WJ
Clin Exp Allergy; 2002 Nov; 32(11):1635-43. PubMed ID: 12569986
[TBL] [Abstract][Full Text] [Related]
30. The ins and outs of MHC class II-mediated antigen processing and presentation.
Roche PA; Furuta K
Nat Rev Immunol; 2015 Apr; 15(4):203-16. PubMed ID: 25720354
[TBL] [Abstract][Full Text] [Related]
31. MHC class II presentation of endogenous tumor antigen by cellular vaccines depends on the endocytic pathway but not H2-M.
Qi L; Ostrand-Rosenberg S
Traffic; 2000 Feb; 1(2):152-60. PubMed ID: 11208095
[TBL] [Abstract][Full Text] [Related]
32. Protein degradation in MHC class II antigen presentation: opportunities for immunomodulation.
Medd PG; Chain BM
Semin Cell Dev Biol; 2000 Jun; 11(3):203-10. PubMed ID: 10906277
[TBL] [Abstract][Full Text] [Related]
33. Formation of complexes between self-peptides and MHC class II molecules in cells defective for presentation of exogenous protein antigens.
Bikoff EK
J Immunol; 1992 Jul; 149(1):1-8. PubMed ID: 1318896
[TBL] [Abstract][Full Text] [Related]
34. A mutant antigen-presenting cell defective in antigen presentation expresses class II MHC molecules with an altered conformation.
Dang LH; Lien LL; Benacerraf B; Rock KL
J Immunol; 1993 May; 150(10):4206-17. PubMed ID: 8482833
[TBL] [Abstract][Full Text] [Related]
35. Major histocompatibility complex class II-peptide complexes internalize using a clathrin- and dynamin-independent endocytosis pathway.
Walseng E; Bakke O; Roche PA
J Biol Chem; 2008 May; 283(21):14717-27. PubMed ID: 18378669
[TBL] [Abstract][Full Text] [Related]
36. Role of APC in the selection of immunodominant T cell epitopes.
Ma C; Whiteley PE; Cameron PM; Freed DC; Pressey A; Chen SL; Garni-Wagner B; Fang C; Zaller DM; Wicker LS; Blum JS
J Immunol; 1999 Dec; 163(12):6413-23. PubMed ID: 10586031
[TBL] [Abstract][Full Text] [Related]
37. Disruption of MHC class II-restricted antigen presentation by vaccinia virus.
Li P; Wang N; Zhou D; Yee CS; Chang CH; Brutkiewicz RR; Blum JS
J Immunol; 2005 Nov; 175(10):6481-8. PubMed ID: 16272302
[TBL] [Abstract][Full Text] [Related]
38. Ancient features of the MHC class II presentation pathway, and a model for the possible origin of MHC molecules.
Dijkstra JM; Yamaguchi T
Immunogenetics; 2019 Mar; 71(3):233-249. PubMed ID: 30377750
[TBL] [Abstract][Full Text] [Related]
39. Interaction of HLA-DR and CD74 at the cell surface of antigen-presenting cells by single particle image analysis.
Karakikes I; Morrison IE; O'Toole P; Metodieva G; Navarrete CV; Gomez J; Miranda-Sayago JM; Cherry RJ; Metodiev M; Fernandez N
FASEB J; 2012 Dec; 26(12):4886-96. PubMed ID: 22889831
[TBL] [Abstract][Full Text] [Related]
40. Evidence for invariant chain 85-101 (CLIP) binding in the antigen binding site of MHC class II molecules.
Bangia N; Watts TH
Int Immunol; 1995 Oct; 7(10):1585-91. PubMed ID: 8562503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
